CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants

Hits: 1

A monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline “stands up well” to all variants of the virus, Vir’s president and CEO said. Read More Go To Source